WNT5A is regulated by PAX2 and may be involved in blastemal predominant wilms tumorigenesis

Neoplasia

Volumn 10, Issue 12, 2008, Pages 1470-1480

  Tamimi, Yahya ^a,b   Ekuere, Usukuma ^a   Laughton, Nicholas ^a   Grundy, Paul ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGAROSE; NICKEL; TRANSCRIPTION FACTOR PAX2; WNT5A PROTEIN;

ARTICLE; BLASTEMA; CARCINOGENESIS; CELL STRAIN HEK293; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; DEVELOPMENTAL BIOLOGY; EMBRYO; GEL MOBILITY SHIFT ASSAY; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY; NEPHROBLASTOMA; PRIORITY JOURNAL; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION;

EID: 57349126136     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08442     Document Type: Article

References (49)

1. Beckwith JB (1998). National Wilms Tumor Study: an update for pathologists. Pediatr Dev Pathol 1 (1), 79-84.
2. Beckwith JB, Kiviat NB, and Bonadio JF (1990). Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol 10 (1-2), 1-36.
3. Charles AK, Brown KW, and Berry PJ (1998). Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development. Am J Pathol 153 (3), 991-1000.
4. Park S, Bernard A, Bove KE, Sens DA, Hazen-Martin DJ, Garvin AJ, and Haber DA (1993). Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. Nat Genet 5 (4), 363-367.
5. Van Heyningen V and Hastie ND (1992). Wilms' tumour: reconciling genetics and biology. Trends Genet 8 (1), 16-21.
6. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, et al. (1990). Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60 (3), 509-520.
7. Dahl E, Koseki H, and Balling R (1997). Pax genes and organogenesis. Bioessays 19 (9), 755-765.
8. Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, Douglass EC, and Housman DE (1990). An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 61 (7), 1257-1269.
9. Huang A, Campbell CE, Bonetta L, McAndrews-Hill MS, Chilton-MacNeill S, Coppes MJ, Law DJ, Feinberg AP, Yeger H, and Williams BR (1990). Tissue, developmental, and tumor-specific expression of divergent transcripts in Wilms tumor. Science 250 (4983), 991-994.
10. Treisman J, Harris E, and Desplan C (1991). The paired box encodes a second DNA binding domain in the paired homeo domain protein. Genes Dev 5 (4), 594-604.
11. Brophy PD, Ostrom L, Lang KM, and Dressler GR (2001). Regulation of ureteric bud outgrowth by Pax2-dependent activation of the glial derived neurotrophic factor gene. Development 128 (23), 4747-4756.
12. Dressler GR, Wilkinson JE, Rothenpieler UW, Patterson LT, Williams-Simons L, and Westphal H (1993). Deregulation of Pax-2 expression in transgenic mice generates severe kidney abnormalities. Nature 362 (6415), 65-67.
13. Torres M, Gomez-Pardo E, Dressler GR, and Gruss P (1995). Pax-2 controls multiple steps of urogenital development. Development 121 (12), 4057-4065.
14. Torres M, Gomez-Pardo E, and Gruss P (1996). Pax2 contributes to inner ear patterning and optic nerve trajectory. Development 122 (11), 3381-3391.
15. Dressler GR (1996). Pax-2, kidney development, and oncogenesis. Med Pediatr Oncol 27 (5), 440-444.
16. Dressler GR and Douglass EC (1992). Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor. Proc Natl Acad Sci USA 89 (4), 1179-1183.
17. Eccles MR, Yun K, Reeve AE, and Fidler AE (1995). Comparative in situ hybridization analysis of PAX2, PAX8, and WT1 gene transcription in human fetal kidney and Wilms' tumors. Am J Pathol 146 (1), 40-45.
18. Dziarmaga A, Hueber PA, Iglesias D, Hache N, Jeffs A, Gendron N, Mackenzie A, Eccles M, and Goodyer P (2006). Neuronal apoptosis inhibitory protein (NAIP) is expressed in developing kidney and is regulated by PAX2. Am J Physiol Renal Physiol 291 (4), F913-F920.
19. +/- mutant mice. Hum Mol Genet 9 (1), 1-11.
20. Sanyanusin P, McNoe LA, Sullivan MJ, Weaver RG, and Eccles MR (1995). Mutation of PAX2 in two siblings with renal-coloboma syndrome. Hum Mol Genet 4 (11), 2183-2184.
21. Sanyanusin P, Schimmenti LA, McNoe LA, Ward TA, Pierpont ME, Sullivan MJ, Dobyns WB, and Eccles MR (1995). Mutation of the PAX2 gene in a family with optic nerve colobomas, renal anomalies and vesicoureteral reflux. Nat Genet 9 (4), 358-364.
22. Torban E, Eccles MR, Favor J, and Goodyer PR (2000). PAX2 suppresses apoptosis in renal collecting duct cells. Am J Pathol 157 (3), 833-842.
23. Dziarmaga A, Clark P, Stayner C, Julien JP, Torban E, Goodyer P, and Eccles M (2003). Ureteric bud apoptosis and renal hypoplasia in transgenic PAX2-Bax fetal mice mimics the renal-coloboma syndrome. J Am Soc Nephrol 14 (11), 2767-2774.
24. Clark P, Dziarmaga A, Eccles M, and Goodyer P (2004). Rescue of defective branching nephrogenesis in renal-coloboma syndrome by the caspase inhibitor, Z-VAD-fmk. J Am Soc Nephrol 15 (2), 299-305.
25. Tamimi Y, Dietrich K, Stone K, and Grundy P (2006). Paired box genes, PAX-2 and PAX-8, are not frequently mutated in Wilms tumor. Mutat Res 601 (1-2), 46-50.
26. Tamimi Y, Lines M, Coca-Prados M, and Walter MA (2004). Identification of target genes regulated by FOXC1 using nickel agarose-based chromatin enrichment. Invest Ophthalmol Vis Sci 45 (11), 3904-3913.
27. Weinmann AS and Farnham PJ (2002). Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods 26 (1), 37-47.
28. Weinmann AS, Yan PS, Oberley MJ, Huang TH, and Farnham PJ (2002). Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes Dev 16 (2), 235-244.
29. Phelps DE and Dressler GR (1996). Identification of novel Pax-2 binding sites by chromatin precipitation. J Biol Chem 271 (14), 7978-7985.
30. Birney E, Andrews D, Bevan P, Caccamo M, Cameron G, Chen Y, Clarke L, Coates G, Cox T, Cuff J, et al. (2004). Ensembl 2004. Nucleic Acids Res 32 (Database issue), D468-D470.
31. Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, et al. (2005). Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 23 (29), 7312-7321.
32. Winer J, Jung CK, Shackel I, and Williams PM (1999). Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270 (1), 41-49.
33. Dressler GR (2006). The cellular basis of kidney development. Annu Rev Cell Dev Biol 22, 509-529.
34. Sredni ST, de Camargo B, Lopes LF, Teixeira R, and Simpson A (2001). Immunohistochemical detection of p53 protein expression as a prognostic indicator in Wilms tumor. Med Pediatr Oncol 37 (5), 455-458.
35. Szuhai K, Ijszenga M, Tanke HJ, Rosenberg C, and Hogendoom PC (2006). Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines. Cancer Genet Cytogenet 166 (2), 173-179.
36. Saitoh T and Katoh M (2002). Expression and regulation of WNT5A and WNT5B in human cancer: up-regulation of WNT5A by TNFalpha in MKN45 cells and up-regulation of WNT5B by beta-estradiol in MCF-7 cells. Int J Mol Med 10 (3), 345-349.
37. Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Roberts D, Fletcher J, Shipman R, Rheinwald J, Demetri G, et al. (1993). The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 4 (4), 415-420.
38. Barasch J, Pressler L, Connor J, and Malik A (1996). A ureteric bud cell line induces nephrogenesis in two steps by two distinct signals. Am J Physiol 271 (1 Pt 2), F50-F61.
39. Hastie ND (1994). The genetics of Wilms' tumor - a case of disrupted development. Annu Rev Genet 28, 523-558.
40. Martin V, Agirre X, Jimenez-Velasco A, Jose-Eneriz ES, Cordeu L, Garate L, Vilas-Zornoza A, Castillejo JA, Heiniger A, Prosper F, et al. (2008). Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia-positive acute lymphoblastic leukemia. Cancer Sci 99, 1865-1868.
41. Li C, Hu L, Xiao J, Chen H, Li JT, Bellusci S, Delanghe S, and Minoo P (2005). Wnt5a regulates Shh and Fgf10 signaling during lung development. Dev Biol 287 (1), 86-97.
42. Mericskay M, Kitajewski J, and Sassoon D (2004). Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus. Development 131 (9), 2061-2072.
43. Grote D, Souabni A, Busslinger M, and Bouchard M (2006). Pax2/8-regulated Gata3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development 133 (1), 53-61.
44. Narlis M, Grote D, Gaitan Y, Boualia SK, and Bouchard M (2007). Pax2 and pax8 regulate branching morphogenesis and nephron differentiation in the developing kidney. J Am Soc Nephrol 18 (4), 1121-1129.
45. Ryan G, Steele-Perkins V, Morris JF, Rauscher FJ, and Dressler GR (1995). Repression of Pax-2 by WT1 during normal kidney development. Development 121 (3), 867-875.
46. Beland M and Bouchard M (2006). PAX gene function during kidney tumorigenesis: a comparative approach. Bull Cancer 93 (9), 875-882.
47. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, and Maccoss MJ (2007). Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 316 (5827), 1043-1046.
48. Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J, Waterman M, Shibuya H, Moon RT, Ninomiya-Tsuji J, and Matsumoto K (2003). The TAK1-NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell Biol 23 (1), 131-139.
49. Yamaguchi TP, Bradley A, McMahon AP, and Jones S (1999). A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development 126 (6), 1211-1223.